drugset / Trial / NCT06455722

[68Ga]Ga-P15-041 PET/CT in Variety of Bone Tumors

NCT06455722 ↗

NaSingle-groupOpen-labelDiagnostic

Summary

Bone tumors refer to tumors that occur in the bone or its accessory tissues. Benign bone tumors usually reveal a good prognosis, while malignant bone tumors develop rapidly, have a poor prognosis and high mortality. Malignant bone tumors are also classified as primary tumor and secondary metastasis. Bone metastasis refers the metastasis of malignant tumors to the bone through lymph, blood or direct invasion to generate daughter tumors, which is the most common bone tumor. More than 40% of patients with malignant tumors will have bone metastasis, among which breast cancer, prostate cancer is more common. Early diagnosis of a various of bone tumors can lay the foundation for clinical implementation of effective treatment measures. The laboratory of Hank F. Kung at the University of Pennsylvania had developed a new generation of Gallium-68 labeled radiopharmaceutical P15-041 (\[68Ga\]Ga-P15-041) based on existing phosphonate-targeting molecular probes. Series of research results showed that \[68Ga\]Ga-P15-041 had high uptake in the bone cortex, blood and other tissues cleared quickly. Hence, \[68Ga\]Ga-P15-041 had the potential to become a new generation of excellent phosphonate molecular probes.

Timeline

Start
2024-01-01
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject [68Ga]Ga-P15-041 Diagnostic / imaging agent 111 mbq Intravenous
Subject [68Ga]Ga-P15-041 Diagnostic / imaging agent 148 mbq Intravenous

Indications